R.E.C. Henrar

556 total citations
23 papers, 448 citations indexed

About

R.E.C. Henrar is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, R.E.C. Henrar has authored 23 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in R.E.C. Henrar's work include Cancer therapeutics and mechanisms (9 papers), Cancer Treatment and Pharmacology (6 papers) and Bioactive Compounds and Antitumor Agents (4 papers). R.E.C. Henrar is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Cancer Treatment and Pharmacology (6 papers) and Bioactive Compounds and Antitumor Agents (4 papers). R.E.C. Henrar collaborates with scholars based in Netherlands, Spain and Belgium. R.E.C. Henrar's co-authors include Jos H. Beijnen, Glynn Faircloth, A. Bult, S.C. Mastbergen, Albert A. Geldof, Gilberto Schwartsmann, José Jimeno, Dan Berger, Herbert M. Pinedo and Hans R. Hendriks and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, British Journal of Cancer and Annals of Oncology.

In The Last Decade

R.E.C. Henrar

23 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.E.C. Henrar Netherlands 14 244 125 116 82 62 23 448
G. FRANCESCHI Italy 14 274 1.1× 176 1.4× 223 1.9× 41 0.5× 34 0.5× 33 714
Yukinori Take Japan 13 193 0.8× 131 1.0× 140 1.2× 52 0.6× 69 1.1× 18 586
Monique Ollier France 12 298 1.2× 79 0.6× 180 1.6× 50 0.6× 132 2.1× 16 586
Brian W. Fox United Kingdom 14 334 1.4× 171 1.4× 268 2.3× 85 1.0× 90 1.5× 35 721
B. R. Winterhalter Germany 10 168 0.7× 141 1.1× 121 1.0× 57 0.7× 27 0.4× 15 396
Steven J. Woodhead United Kingdom 13 534 2.2× 167 1.3× 263 2.3× 37 0.5× 22 0.4× 19 889
Ioana Abraham China 7 243 1.0× 220 1.8× 53 0.5× 53 0.6× 27 0.4× 7 423
João F. S. Carvalho Portugal 9 287 1.2× 54 0.4× 182 1.6× 25 0.3× 41 0.7× 12 522
Stéphane Acoca Canada 6 600 2.5× 176 1.4× 55 0.5× 53 0.6× 17 0.3× 7 784
Crescent R. Isham United States 10 354 1.5× 255 2.0× 93 0.8× 53 0.6× 31 0.5× 14 686

Countries citing papers authored by R.E.C. Henrar

Since Specialization
Citations

This map shows the geographic impact of R.E.C. Henrar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.E.C. Henrar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.E.C. Henrar more than expected).

Fields of papers citing papers by R.E.C. Henrar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.E.C. Henrar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.E.C. Henrar. The network helps show where R.E.C. Henrar may publish in the future.

Co-authorship network of co-authors of R.E.C. Henrar

This figure shows the co-authorship network connecting the top 25 collaborators of R.E.C. Henrar. A scholar is included among the top collaborators of R.E.C. Henrar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.E.C. Henrar. R.E.C. Henrar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nuijen, Bastiaan, Marjan Bouma, R.E.C. Henrar, et al.. (2000). In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS. International Journal of Pharmaceutics. 194(2). 261–267. 13 indexed citations
2.
Nuijen, Bastiaan, Marjan Bouma, R.E.C. Henrar, et al.. (2000). Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.. PubMed. 54(3). 193–208. 24 indexed citations
3.
Sparidans, Rolf W., Olaf van Tellingen, R.E.C. Henrar, et al.. (1999). Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4′-hydrazino-2-stilbazole. Journal of Chromatography B Biomedical Sciences and Applications. 729(1-2). 43–53. 16 indexed citations
4.
Sparidans, Rolf W., et al.. (1999). Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications. 726(1-2). 255–260. 5 indexed citations
5.
6.
Geldof, Albert A., S.C. Mastbergen, R.E.C. Henrar, & Glynn Faircloth. (1999). Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemotherapy and Pharmacology. 44(4). 312–318. 52 indexed citations
7.
Rosing, Hilde, M. J. X. Hillebrand, José Jimeno, et al.. (1998). Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Mass Spectrometry. 33(11). 1134–1140. 46 indexed citations
8.
Rosing, Hilde, H. Talsma, R.E.C. Henrar, et al.. (1998). Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11}. Investigational New Drugs. 16(2). 99–111. 2 indexed citations
9.
Tellingen, Olaf van, Cornelis J. A. Punt, R.E.C. Henrar, et al.. (1998). A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemotherapy and Pharmacology. 41(5). 377–384. 11 indexed citations
10.
Rosing, Hilde, José Jimeno, Glynn Faircloth, et al.. (1998). Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction. Journal of Chromatography B Biomedical Sciences and Applications. 710(1-2). 183–189. 20 indexed citations
11.
Underberg, W.J.M., et al.. (1997). Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.. PubMed. 51(2). 89–95. 3 indexed citations
12.
Henrar, R.E.C., et al.. (1996). Systematic Study on the Chemical Stability of the Prodrug Antitumor Agent Carzelesin (U-80,244). Journal of Pharmaceutical Sciences. 85(11). 1227–1233. 1 indexed citations
13.
Beijnen, Jos H., Karl P. Flora, Gavin Halbert, R.E.C. Henrar, & J A Slack. (1995). CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. British Journal of Cancer. 72(1). 210–218. 20 indexed citations
14.
Tellingen, Olaf van, et al.. (1994). Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 652(1). 51–58. 4 indexed citations
15.
Talsma, H., et al.. (1994). Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. Cancer Chemotherapy and Pharmacology. 34(5). 416–422. 7 indexed citations
16.
Henrar, R.E.C., et al.. (1994). Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244). Investigational New Drugs. 12(4). 303–314. 5 indexed citations
17.
Hendriks, Hans R., Dan Berger, M.C. Bibby, et al.. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer. 29(6). 897–906. 89 indexed citations
18.
Hendriks, Hans R., Jacqueline Plowman, Dan Berger, et al.. (1992). Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Annals of Oncology. 3(9). 755–763. 25 indexed citations
19.
Graham, Marien Alet, D. Bissett, A Setanoians, et al.. (1992). Prelinical and Phase I Studies With Rhizoxin to Apply a Pharmacokinetically Guided Dose-Escalation Scheme. JNCI Journal of the National Cancer Institute. 84(7). 494–500. 21 indexed citations
20.
Bissett, D., Martin A. Graham, A Setanoians, et al.. (1992). Phase I and pharmacokinetic study of rhizoxin.. PubMed. 52(10). 2894–8. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. FRANCESCHI Breakdown of academic impact, for papers by Yukinori Take Breakdown of academic impact, for papers by Monique Ollier Breakdown of academic impact, for papers by Brian W. Fox Breakdown of academic impact, for papers by B. R. Winterhalter Breakdown of academic impact, for papers by Steven J. Woodhead Breakdown of academic impact, for papers by Ioana Abraham Breakdown of academic impact, for papers by João F. S. Carvalho Breakdown of academic impact, for papers by Stéphane Acoca Breakdown of academic impact, for papers by Crescent R. Isham
Rankless by CCL
2026